MOTS-c dosage reference: typical range 5 – 15 mg, 2–3×/week, cycle 4–8 weeks on, 2–4 weeks off. Titration chart, reconstitution math and storage.
Mitochondrial-derived peptide that acts as an exercise mimetic. Enhances metabolic function, insulin sensitivity, and cellular energy.
Published protocol literature for MOTS-c describes a typical range of 5 – 15 mg, dosed 2–3×/week, over a cycle of 4–8 weeks on, 2–4 weeks off. Reported half-life: short (minutes, free peptide).
| Parameter | Reported value |
|---|---|
| Typical dose range | 5 – 15 mg |
| Frequency | 2–3×/week |
| Cycle length | 4–8 weeks on, 2–4 weeks off |
| Half-life | Short (minutes, free peptide) |
| Route | Subcutaneous injection (most published protocols) |
| Diluent | Bacteriostatic water |
| Commonly stacked with | BPC-157 (gut-brain axis), NAD+ precursors, Semaglutide |
Protocols are usually titrated rather than started at the top of the range. The tiers below reflect how MOTS-c dosing is commonly stepped in the published protocol literature.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 5 mg | 2×/week | Metabolic and energy baseline |
| Intermediate | 10 mg | 2×/week | Enhanced endurance and cognition |
| Advanced | 15 mg | 3×/week | Maximum metabolic/cognitive effects |
Concentration in mcg/mL equals vial milligrams multiplied by 1000, divided by the millilitres of bacteriostatic water added. Volume per dose in mL equals the target dose in mcg divided by that concentration. On a U-100 insulin syringe, multiply the volume in mL by 100 to read the units.
| Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|
| 2 mg vial | 1 mL bacteriostatic water | 2,000 mcg/mL |
| 5 mg vial | 2 mL bacteriostatic water | 2,500 mcg/mL |
| 10 mg vial | 2 mL bacteriostatic water | 5,000 mcg/mL |
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
Dose ranges on this page summarise published research and practitioner protocol literature for MOTS-c. They are a reference, not medical direction. All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Published protocol literature for MOTS-c generally describes 5 – 15 mg, administered 2–3×/week. Individual protocols vary and should be set by a licensed practitioner.
2–3×/week. Frequency is driven by half-life — MOTS-c has a reported half-life of short (minutes, free peptide), so shorter-acting compounds are dosed more often.
Typical cycle length reported is 4–8 weeks on, 2–4 weeks off. Cycling exists to limit receptor desensitisation and to create assessment windows, not as a fixed rule.
2mg → 1ml bacteriostatic water; 5mg → 2ml bacteriostatic water; 10mg → 2ml bacteriostatic water. Concentration in mcg/mL equals vial milligrams times 1000 divided by millilitres of bacteriostatic water.
It is encoded by mitochondrial DNA rather than nuclear DNA — one of only a handful of known mitochondrial-derived peptides.